Agathangelidis Andreas, Sutton Lesley Ann, Hadzidimitriou Anastasia, Tresoldi Cristina, Langerak Anton W, Belessi Chrysoula, Davi Frederic, Rosenquist Richard, Stamatopoulos Kostas, Ghia Paolo
Institute of Applied Biosciences, Centre for Research and Technology Hellas;
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University; Department of Molecular Medicine and Surgery, Karolinska Institutet;
J Vis Exp. 2018 Nov 26(141). doi: 10.3791/57787.
During B cell maturation, the complex process of immunoglobulin (IG) gene V(D)J recombination coupled with somatic hypermutation (SHM) gives rise to a unique DNA sequence within each individual B cell. Since B cell malignancies result from the clonal expansion of a single cell, IG genes represent a unique molecular signature common to all the malignant cells within an individual patient; thus, IG gene rearrangements can be used as clonal markers. In addition to serving as an important clonal identifier, the IG gene sequence can act as a 'molecular timeline' since it is associated with specific developmental stages and hence reflects the history of the B cell involved in the neoplastic transformation. Moreover, for certain malignancies, in particular chronic lymphocytic leukemia (CLL), the IG gene sequence holds prognostic and potentially predictive capabilities. That said, extrapolating meaningful conclusions from IG gene sequence analysis would be impossible if robust methods and tools were not available to aid in their analysis. This article, drawing on the vast experience of the European Research Initiative on CLL (ERIC), details the technical aspects and essential requirements necessary to ensure reliable and reproducible IG gene sequence analysis in CLL, a test that is now recommended for all CLL patients prior to treatment. More specifically, the various analytical stages are described ranging from the identification of the clonotypic IG gene rearrangement and the determination of the nucleotide sequence to the accurate clinical interpretation of the IG gene sequence data.
在B细胞成熟过程中,免疫球蛋白(IG)基因V(D)J重组与体细胞超突变(SHM)这一复杂过程,使得每个个体B细胞内产生独特的DNA序列。由于B细胞恶性肿瘤是由单个细胞的克隆性扩增导致的,IG基因代表了个体患者所有恶性细胞共有的独特分子特征;因此,IG基因重排可作为克隆标记。除了作为重要的克隆标识符外,IG基因序列还可充当“分子时间线”,因为它与特定的发育阶段相关,从而反映参与肿瘤转化的B细胞的历史。此外,对于某些恶性肿瘤,特别是慢性淋巴细胞白血病(CLL),IG基因序列具有预后和潜在的预测能力。也就是说,如果没有强大的方法和工具来辅助分析,就不可能从IG基因序列分析中推断出有意义的结论。本文借鉴欧洲慢性淋巴细胞白血病研究倡议(ERIC)的丰富经验,详细介绍了在CLL中确保可靠且可重复的IG基因序列分析所需的技术方面和基本要求,这一检测现在推荐用于所有CLL患者治疗前。更具体地说,描述了从克隆型IG基因重排的鉴定、核苷酸序列的确定到IG基因序列数据的准确临床解读等各个分析阶段。